Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Vertex is already looking beyond the triple therapy concept, towards a Gene Editing mRNA drug, which it says could help the entire global population of CF patients, which is up to 75,000 patients ...

I am not a biotech expert, but I could not ignore the strength of Vertex's CF drug portfolio in 2022. The stock has almost doubled since then. While continuing to invest in innovative CF ...

And van Goor, who has led development of CF drugs at Vertex since 2001 has warned that there is still much work to do to find ways to correct all the different mutations that lead to the disease.

Vertex has built its earnings thanks to its CF program, and with a new CF drug approved a few months ago, the company may be ...

(Reuters) -Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta. However, the drugmaker ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals Inc. raised its sales expectations for the year, citing continued growth of its cystic fibrosis drugs and the launch of its new treatment for sickle cell disease. Vertex now ...

Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be ...

May 5 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF ...